CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign

HOLLY SPRINGS, N.C., Sept. 29, 2026 // -- CSL Seqirus, a business of CSL (ASX:CSL), today announced expanded availability of influenza vaccine in the United States following the successful completion of its 2026/27 manufacturing campaign.With the majority of customer orders already shippe…